Providing progressive cancer treatment and compassionate care.

Drug Dictionary – Biological Therapy

Drug Dictionary Index

  • adalimumab-atto

    Class: Biosimilar Generic Name: adalimumab-atto Trade Name: Amjevita™ For which conditions is this drug indicated? Amjevita is indicated for use in several types of arthritis: rheumatoid (RA), juvenile idiopathic (JIA), psoriatic (PsA), and ankylosing spondylitis (AS). It is also used for adult Crohn’s disease (CD) and ulcerative colitis (UC) where conventional therapies have been inadequate; and for the treatment […]

  • Amjevita™

    Class: Biosimilar Generic Name: adalimumab-atto Trade Name: Amjevita™ For which conditions is this drug indicated? Amjevita is indicated for use in several types of arthritis: rheumatoid (RA), juvenile idiopathic (JIA), psoriatic (PsA), and ankylosing spondylitis (AS). It is also used for adult Crohn’s disease (CD) and ulcerative colitis (UC) where conventional therapies have been inadequate; and for the treatment […]

  • Tecentriq®

    Class: Biological Therapy Generic Name: atezolizumab Trade Name: Tecentriq® How is this drug used? Tecentriq is approved for patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following therapy with a platinum agent. Patients with EGFR or ALK gene abnormalities may receive Tecentriq if FDA-approved therapies for these conditions are no longer working. Tecentriq is also […]

  • atezolizumab

    Class: Biological Therapy Generic Name: atezolizumab Trade Name: Tecentriq® How is this drug used? Tecentriq is approved for patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following therapy with a platinum agent. Patients with EGFR or ALK gene abnormalities may receive Tecentriq if FDA-approved therapies for these conditions are no longer working. Tecentriq is also […]

  • Praxbind®

    Class: Biologic Therapy Generic Name: idarucizumab Trade Name: Praxbind For which conditions is this drug approved? Praxbind® is indicated for patients specifically treated with Pradaxa® (dabigatran etexilate mesylate), an anti-clotting agent, when reversal of the anti-clotting effects of the agent is needed for emergency procedures, life-threatening instances, or uncontrolled bleeding. What is the mechanism of action?  Praxbind is a […]

  • idarucizumab

    Class: Biologic Therapy Generic Name: idarucizumab Trade Name: Praxbind For which conditions is this drug approved? Praxbind® is indicated for patients specifically treated with Pradaxa® (dabigatran etexilate mesylate), an anti-clotting agent, when reversal of the anti-clotting effects of the agent is needed for emergency procedures, life-threatening instances, or uncontrolled bleeding. What is the mechanism of action?  Praxbind is a […]

  • Venclexta®

    Class: Biological Therapy Generic Name: Venetoclax Trade Name: Venclexta® How is this drug used? Venclexta is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a specific chromosomal abnormality, referred to as a 17p deletion. Patients must have received at least one prior therapeutic regimen before starting treatment with Venclexta. What is the mechanism of […]

  • Venetoclax

    Class: Biological Therapy Generic Name: Venetoclax Trade Name: Venclexta® How is this drug used? Venclexta is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a specific chromosomal abnormality, referred to as a 17p deletion. Patients must have received at least one prior therapeutic regimen before starting treatment with Venclexta. What is the mechanism of […]

  • Cabometyx™

    Class: Biological Therapy Generic Name: cabozantinib Trade Name: Cabometyx™ How is this drug used? Cabometyx is indicated for patients with advanced renal cell carcinoma (RCC) who have already been treated with prior anti-angiogenic therapy. What is the mechanism of action? Cabometyx is a kinase inhibitor that binds to certain protein receptors on cells known as MET, AXL, and VEGFR-1, -2, and […]

  • cabozantinib

    Class: Biological Therapy Generic Name: cabozantinib Trade Name: Cabometyx™ How is this drug used? Cabometyx is indicated for patients with advanced renal cell carcinoma (RCC) who have already been treated with prior anti-angiogenic therapy. What is the mechanism of action? Cabometyx is a kinase inhibitor that binds to certain protein receptors on cells known as MET, AXL, and VEGFR-1, -2, and […]

  • Crizotinib

    Class: Biological Therapy Generic Name: Crizotinib Trade Name: Xalkori® How is this drug used? Xalkori is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors test positive for an abnormality in the anaplastic lymphoma kinase (ALK) gene, or whose tumors are  ROS1-positive. What is the mechanism of action? Between one […]

  • Imlygic™

    Class: Viral Therapy Generic Name: talimogene laherparepvec Trade Name: Imlygic™ For which conditions is this drug approved? Imlygic can be used to treat melanomas in the skin or lymph nodes that can’t be removed with surgery. What is the mechanism of action?  Imlygic is a herpes germ that has been altered to infect and kill cancer cells. These altered […]

  • talimogene laherparepvec

    Class: Viral Therapy Generic Name: talimogene laherparepvec Trade Name: Imlygic™ For which conditions is this drug approved? Imlygic can be used to treat melanomas in the skin or lymph nodes that can’t be removed with surgery. What is the mechanism of action?  Imlygic is a herpes germ that has been altered to infect and kill cancer cells. These altered […]

  • Cotellic™

    Class: Biological Therapy Generic Name: cobimetinib Trade Name: Cotellic™ For which conditions is this drug approved? Cotellic is a kinase inhibitor used for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with Zelboraf (vemurafenib). What is the mechanism of action?  A series of proteins called the MAPK cell signaling […]

  • cobimetinib

    Class: Biological Therapy Generic Name: cobimetinib Trade Name: Cotellic™ For which conditions is this drug approved? Cotellic is a kinase inhibitor used for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with Zelboraf (vemurafenib). What is the mechanism of action?  A series of proteins called the MAPK cell signaling […]

  • Tagrisso

    Class: Biological Therapy Generic Name: Osimertinib Trade Name: Tagrisso™ For which conditions is this drug approved? Tagrisso is a kinase inhibitor used to treat patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) whose cancer has progressed on or after EGFR tyrosine kinase inhibitor therapy. What is the mechanism of action? Some non-small […]

  • Osimertinib

    Class: Biological Therapy Generic Name: Osimertinib Trade Name: Tagrisso™ For which conditions is this drug approved? Tagrisso is a kinase inhibitor used to treat patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) whose cancer has progressed on or after EGFR tyrosine kinase inhibitor therapy. What is the mechanism of action? Some non-small […]

  • Darzalex®

    Class: Biological Therapy Generic Name: daratumumab Trade Name: Darzalex® How is this drug used? Darzalex is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy; or in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, in patients who have received at least one prior therapy. What is the […]

  • daratumumab

    Class: Biological Therapy Generic Name: daratumumab Trade Name: Darzalex® How is this drug used? Darzalex is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy; or in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, in patients who have received at least one prior therapy. What is the […]

  • Ninlaro®

    Class: Biological Therapy Generic Name: Ixazomib Trade Name: Ninlaro® For which conditions is this drug approved? Ninlaro is approved for use in combination with the medicines Revlimid® (lenalidomide) and dexamethasone to treat people with multiple myeloma who have received at least one prior treatment. What is the mechanism of action? Ninlaro is a type of […]

  • Ixazomib

    Class: Biological Therapy Generic Name: Ixazomib Trade Name: Ninlaro® For which conditions is this drug approved? Ninlaro is approved for use in combination with the medicines Revlimid® (lenalidomide) and dexamethasone to treat people with multiple myeloma who have received at least one prior treatment. What is the mechanism of action? Ninlaro is a type of […]

  • Imlygic®

    Class: Biological Therapy Generic Name: Talimogene Laherparepvec Trade Name: Imlygic® For which conditions is this drug approved? Imlygic is approved to treat patients with advanced melanoma that has come back after initial surgery. What is the mechanism of action? Imlygic is a type of immunotherapy that uses a specially designed virus to destroy cancer cells. […]

  • Talimogene Laherparepvec

    Class: Biological Therapy Generic Name: Talimogene Laherparepvec Trade Name: Imlygic® For which conditions is this drug approved? Imlygic is approved to treat patients with advanced melanoma that has come back after initial surgery. What is the mechanism of action? Imlygic is a type of immunotherapy that uses a specially designed virus to destroy cancer cells. […]

  • Portrazza®

    Class: Biological Therapy Generic Name: Necitumumab Trade Name: Portrazza® For which conditions is this drug approved? Portrazza is approved for use in combination with the chemotherapy drugs Gemzar® (gemcitabine) and Platinol® cisplatin for first-line treatment of patients with metastatic squamous non-small cell lung cancer. What is the mechanism of action? Portrazza belongs to a class […]

  • Necitumumab

    Class: Biological Therapy Generic Name: Necitumumab Trade Name: Portrazza® For which conditions is this drug approved? Portrazza is approved for use in combination with the chemotherapy drugs Gemzar® (gemcitabine) and Platinol® cisplatin for first-line treatment of patients with metastatic squamous non-small cell lung cancer. What is the mechanism of action? Portrazza belongs to a class […]

  • Empliciti®

    Class: Biological Therapy Generic Name: Elotuzumab Trade Name: Empliciti® For which conditions is this drug approved? Empliciti is approved to treat patients with multiple myeloma who have received one to three prior treatments. Empliciti is given in combination with the medicines Revlimid® (lenalidomide) and dexamethasone. What is the mechanism of action? Empliciti belongs to a […]

  • Elotuzumab

    Class: Biological Therapy Generic Name: Elotuzumab Trade Name: Empliciti® For which conditions is this drug approved? Empliciti is approved to treat patients with multiple myeloma who have received one to three prior treatments. Empliciti is given in combination with the medicines Revlimid® (lenalidomide) and dexamethasone. What is the mechanism of action? Empliciti belongs to a […]

  • Vistogard®

    Class: Biological Therapy Generic Name: Uridine Triacetate Trade Name: Vistogard® For which conditions is this drug approved? Vistogard is approved for the emergency treatment of adults and children who have received an overdose of one of the following chemotherapy medicines: fluorouracil or Xeloda® (capecitabine). Vistogard can be used in patients with or without symptoms of […]

  • Uridine Triacetate

    Class: Biological Therapy Generic Name: Uridine Triacetate Trade Name: Vistogard® For which conditions is this drug approved? Vistogard is approved for the emergency treatment of adults and children who have received an overdose of one of the following chemotherapy medicines: fluorouracil or Xeloda® (capecitabine). Vistogard can be used in patients with or without symptoms of […]

  • Alecensa®

    Class: Biological Therapy Generic Name: alectinib Trade Name: Alecensa® For which conditions is this drug approved? Alecensa is approved to treat patients with non-small cell lung cancer (NSCLC) that has a mutation in the anaplastic lymphoma kinase (ALK) gene and has spread to other parts of the body. Alecensa is also approved for patients who have […]

  • alectinib

    Class: Biological Therapy Generic Name: alectinib Trade Name: Alecensa® For which conditions is this drug approved? Alecensa is approved to treat patients with non-small cell lung cancer (NSCLC) that has a mutation in the anaplastic lymphoma kinase (ALK) gene and has spread to other parts of the body. Alecensa is also approved for patients who have […]

  • brentuximab vedotin

    Class: Biological Therapy and Chemotherapy Generic Name: brentuximab vedotin Trade Name: Adcetris® How is this drug used? Adcetris is used for the treatment of Hodgkin lymphoma that has progressed after autologous stem cell transplant or has progressed after at least two prior multi-agent chemotherapy regimens in patients who are not candidates for a stem cell […]

  • ipilimumab

    Class: Biological Therapy Generic Name: ipilimumab Trade Name: Yervoy™ How is this drug used? Yervoy is used for the treatment of metastatic melanoma or melanoma that cannot be surgically removed, and for an additional indication of adjuvant treatment of patients with cutaneous melanoma involving nearby lymph nodes of more than 1 mm who have undergone complete resection […]

  • Gazyva®

    Class: Biological therapy Generic Name: Obinutuzumab Trade Name: Gazyva® For which conditions is this drug approved? Gazyva is approved for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) in combination with the chemotherapy drug Leukeran® (chlorambucil). Gazyva is also indicated for patients with follicular lymphoma (FL) in combination with Treanda® (bendamustine), followed by therapy […]

  • Obinutuzumab

    Class: Biological therapy Generic Name: Obinutuzumab Trade Name: Gazyva® For which conditions is this drug approved? Gazyva is approved for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) in combination with the chemotherapy drug Leukeran® (chlorambucil). Gazyva is also indicated for patients with follicular lymphoma (FL) in combination with Treanda® (bendamustine), followed by therapy […]

  • Sonidegib

    Class: Biological Therapy Generic Name: Odomzo® Trade Name: Sonidegib For which conditions is this drug approved? Odomzo is approved for the treatment of adults with a type of skin cancer called basal cell carcinoma (BCC). Specifically, Odomzo is used in BCC that has come back following surgery or radiation or that cannot be treated with […]

  • Odomzo®

    Class: Biological Therapy Generic Name: Odomzo® Trade Name: Sonidegib For which conditions is this drug approved? Odomzo is approved for the treatment of adults with a type of skin cancer called basal cell carcinoma (BCC). Specifically, Odomzo is used in BCC that has come back following surgery or radiation or that cannot be treated with […]

  • Enbrel®

    Class: Biological Therapy Generic Name: Etanercept  Trade Name: Enbrel® For which conditions is this drug approved? Enbrel is approved for use in adults who have been diagnosed with the following inflammatory conditions: moderately to severely active rheumatoid arthritis (RA); psoriatic arthritis; ankylosing spondylitis; chronic moderate to severe psoriasis. Enbrel can be used alone or with […]

  • Etanercept

    Class: Biological Therapy Generic Name: Etanercept  Trade Name: Enbrel® For which conditions is this drug approved? Enbrel is approved for use in adults who have been diagnosed with the following inflammatory conditions: moderately to severely active rheumatoid arthritis (RA); psoriatic arthritis; ankylosing spondylitis; chronic moderate to severe psoriasis. Enbrel can be used alone or with […]

  • Filgrastim-sndz

    Class: Biological Therapy Generic Name: Filgrastim-sndz Trade Name: Zarxio™ For which conditions is this drug approved? Zarxio is approved to decrease the incidence of infection in patients with a low neutrophil (type of white blood cell that helps fight infection) count due to cancer treatment, a condition called neutropenia. What is the mechanism of action? […]

  • Zydelig

    Class: Biological Therapy Generic Name: Idelalisib Trade Name: Zydelig® For which conditions is this drug approved? Zydelig is approved to treat patients with three types of blood cancers: chronic lymphocytic leukemia that has returned (relapsed), relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma. What is the mechanism of action? Zydelig is a kinase […]

  • Idelalisib

    Class: Biological Therapy Generic Name: Idelalisib Trade Name: Zydelig® For which conditions is this drug approved? Zydelig is approved to treat patients with three types of blood cancers: chronic lymphocytic leukemia that has returned (relapsed), relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma. What is the mechanism of action? Zydelig is a kinase […]

  • Unituxin

      Class: Biological Therapy Generic Name: Dinutuximab Trade Name: Unituxin™ For which conditions is this drug approved? Unituxin is approved for the treatment of children with high-risk neuroblastoma, a type of cancer that starts in certain very early forms of nerve cells found in an embryo or fetus. What is the mechanism of action? Unituxin […]

  • Dinutuximab

      Class: Biological Therapy Generic Name: dinutuximab Trade Name: Unituxin™ For which conditions is this drug approved? Unituxin is approved for the treatment of children with high-risk neuroblastoma, a type of cancer that starts in certain very early forms of nerve cells found in an embryo or fetus. What is the mechanism of action? Unituxin is […]

  • Lenvima®

    Class: Biological Therapy Generic Name: Lenvatinib Trade Name: Lenvima® For which conditions is this drug approved? Lenvima is approved to treat people with a type of thyroid cancer called differentiated thyroid cancer (DTC) when the disease can no longer be treated with radioactive iodine and is progressing. It is also indicated for patients with advanced renal […]

  • Lenvatinib

    Class: Biological Therapy Generic Name: Lenvatinib Trade Name: Lenvima® For which conditions is this drug approved? Lenvima is approved to treat people with a type of thyroid cancer called differentiated thyroid cancer (DTC) when the disease can no longer be treated with radioactive iodine and is progressing. It is also indicated for patients with advanced renal […]

  • Lynparza™

    Class: Biological Therapy Generic Name: Olaparib Trade Name: Lynparza™ For which conditions is this drug approved? Lynparza is used treat women with advanced ovarian cancer who have: a) received previous treatment with three or more prior chemotherapy medicines or a combination of chemotherapy medicines; and b) have a certain type of abnormal inherited BRCA gene. […]

  • Olaparib

    Class: Biological Therapy Generic Name: Olaparib Trade Name: Lynparza™ For which conditions is this drug approved? Lynparza is used treat women with advanced ovarian cancer who have: a) received previous treatment with three or more prior chemotherapy medicines or a combination of chemotherapy medicines; and b) have a certain type of abnormal inherited BRCA gene. […]

  • Lanreotide

    Class: Biological Therapy Generic Name: Lanreotide Trade Name: Somatuline® Depot For which conditions is this drug approved? Somatuline Depot is approved for: The long-term treatment of people with acromegaly, a hormonal disorder that develops when your pituitary gland produces too much growth hormone during adulthood. Somatuline Depot can be used in these patients when surgery […]

  • Somatuline® Depot

    Class: Biological Therapy Generic Name: Lanreotide Trade Name: Somatuline® Depot For which conditions is this drug approved? Somatuline Depot is approved for: The long-term treatment of people with acromegaly, a hormonal disorder that develops when your pituitary gland produces too much growth hormone during adulthood. Somatuline Depot can be used in these patients when surgery […]

  • Blincyto®

    Class: Biological Therapy Generic Name: blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto® is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL. What is the mechanism of action? Blincyto is a type of drug known as a monoclonal antibody. […]

  • blinatumomab

    Class: Biological Therapy Generic Name: blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto® is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL. What is the mechanism of action? Blincyto is a type of drug known as a monoclonal antibody. […]

  • Inlyta®

    Class: Biological Therapy Generic Name: axitinib Trade Name: Inlyta® For which conditions is this drug approved? Inlyta is approved for the treatment of advanced renal cell carcinoma (kidney cancer) when prior treatment hasn’t worked. What is the mechanism of action? Inlyta is a kinase inhibitor. These drugs work by blocking the action of enzymes called kinases, […]

  • axitinib

    Class: Biological Therapy Generic Name: axitinib Trade Name: Inlyta® For which conditions is this drug approved? Inlyta is approved for the treatment of advanced renal cell carcinoma (kidney cancer) when prior treatment hasn’t worked. What is the mechanism of action? Inlyta is a kinase inhibitor. These drugs work by blocking the action of enzymes called kinases, […]

  • Ibrance®

    Class: Biological Therapy Generic Name: Palbociclib Trade Name: Ibrance® For which conditions is this drug approved? Ibrance is approved in combination with the medicine Femara® (letrozole) for the treatment of postmenopausal women with advanced breast cancer that is estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative for first therapy. It is also used […]

  • Palbociclib

    Class: Biological Therapy Generic Name: palbociclib Trade Name: Ibrance® For which conditions is this drug approved? Ibrance is approved in combination with the medicine Femara® (letrozole) for the treatment of postmenopausal women with advanced breast cancer that is estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative for first therapy. It is also used in […]

  • Opdivo®

    Class: Biological Therapy Generic Name: nivolumab Trade Name: Opdivo® For which conditions is this drug approved? Opdivo is approved to treat melanoma that: a) can’t be removed by surgery; or b) metastatic melanoma that’s progressed after treatment with Yervoy® (ipilimumab) or, if BRAF V600 mutation positive, progressed after treatment with a BRAF inhibitor. Opdivo is also […]

  • nivolumab

    Class: Biological Therapy Generic Name: nivolumab Trade Name: Opdivo® For which conditions is this drug approved? Opdivo is approved to treat melanoma that: a) can’t be removed by surgery; or b) metastatic melanoma that’s progressed after treatment with Yervoy® (ipilimumab) or, if BRAF V600 mutation positive, progressed after treatment with a BRAF inhibitor. Opdivo is also […]

  • Panobinostat

    Class: Biological Therapy Generic Name: Panobinostat Trade Name: Farydak® For which conditions is this drug approved? Farydak® is approved for use, in combination with Velcade® (bortezomib) and dexamethasone, in people with multiple myeloma after they’ve had at least two other types of treatment. What is the mechanism of action? Farydak is an agent known as a […]

  • Farydak®

    Class: Biological Therapy Generic Name: Panobinostat Trade Name: Farydak® For which conditions is this drug approved? Farydak® is approved for use, in combination with Velcade® (bortezomib) and dexamethasone, in people with multiple myeloma after they’ve had at least two other types of treatment. What is the mechanism of action? Farydak is an agent known as a […]

  • Zykadia™

    Class: Biological Therapy Generic Name: ceritinib Trade Name: Zykadia™ For which conditions is this drug approved? Zykadia is approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) that is caused by a defect in a gene called ALK (anaplastic lymphoma kinase) whose disease has worsened after taking Xalkori® (crizotinib) or cannot tolerate […]

  • ceritinib

    Class: Biological Therapy Generic Name: ceritinib Trade Name: Zykadia™ For which conditions is this drug approved? Zykadia is approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) that is caused by a defect in a gene called ALK (anaplastic lymphoma kinase) whose disease has worsened after taking Xalkori® (crizotinib) or cannot tolerate […]

  • Beleodaq®

    Class: Biological Therapy Generic Name: belinostat (be-LIN-oh-stat) Trade Name: Beleodaq® For which conditions is this drug approved? Beleodaq is approved for the treatment of peripheral T-cell lymphoma (PTCL) that comes back or does not respond to treatment. What is the mechanism of action? Beleodaq is an agent known as a histone deacetylase inhibitor. It works by […]

  • belinostat

    Class: Biological Therapy Generic Name: belinostat (be-LIN-oh-stat) Trade Name: Beleodaq® For which conditions is this drug approved? Beleodaq is approved for the treatment of peripheral T-cell lymphoma (PTCL) that comes back or does not respond to treatment. What is the mechanism of action? Beleodaq is an agent known as a histone deacetylase inhibitor. It works by […]

  • Afatinib

    Class: Biological Therapy Generic Name: afatinib Trade Name: Gilotrif® For which conditions is this drug approved? Gilotrif is approved for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have the following epidermal growth factor receptor (EGFR) traits: exon 19 deletions or exon 21 (L858R) substitution mutations. Exons are the protein-coding DNA […]

  • Gilotrif®

    Class: Biological Therapy Generic Name: afatinib Trade Name: Gilotrif® For which conditions is this drug approved? Gilotrif is approved for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have the following epidermal growth factor receptor (EGFR) traits: exon 19 deletions or exon 21 (L858R) substitution mutations. Exons are the protein-coding DNA […]

  • Keytruda®

    Class: Biological Therapy Generic Name: pembrolizumab Trade Name: Keytruda® For which conditions is this drug approved? Keytruda is approved for: a) initial treatment of metastatic melanoma, melanoma that is unresectable and metastatic melanoma with disease progression following treatment with Yervoy® (ipilimumab) and, if BRAF V600 mutation positive, treatment with a BRAF inhibitor, b) treatment of metastatic […]

  • pembrolizumab

    Class: Biological Therapy Generic Name: pembrolizumab Trade Name: Keytruda® For which conditions is this drug approved? Keytruda is approved for: a) initial treatment of metastatic melanoma, melanoma that is unresectable and metastatic melanoma with disease progression following treatment with Yervoy® (ipilimumab) and, if BRAF V600 mutation positive, treatment with a BRAF inhibitor, b) treatment of metastatic […]

  • ofatumumab

    Class: Biological Therapy Generic Name: ofatumumab Trade Name: Arzerra® For which conditions is this drug approved? Arzerra is approved in combination with the chemotherapy drug Leukeran® (chlorambucil) for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) who are not eligible for fludarabine-based therapy (such as Fludara®). Arzerra is also approved for the treatment of […]

  • Arzerra®

    Class: Biological Therapy Generic Name: ofatumumab Trade Name: Arzerra® For which conditions is this drug approved? Arzerra is approved in combination with the chemotherapy drug Leukeran® (chlorambucil) for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) who are not eligible for fludarabine-based therapy (such as Fludara®). Arzerra is also approved for the treatment of […]

  • ramucirumab

    Class: Biological Therapy  Generic Name:  ramucirumab Trade Name:  Cyramza® For which conditions is this drug approved? Cyramza is approved for the treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma on or after flouropyrimidine- or platinum based therapy, and for metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy in combination […]

  • Cyramza®

    Class: Biological Therapy  Generic Name:  ramucirumab Trade Name:  Cyramza® For which conditions is this drug approved? Cyramza is approved for the treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma on or after flouropyrimidine- or platinum based therapy, and for metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy in combination […]

  • Pomalidomide

    Class: Biological Therapy Generic Name:Pomalidomide Trade Name: Pomalyst® For which conditions is this drug approved?Pomalyst is indicated for patients with multiple myeloma who have received at least two prior therapies including Revlimid® (lenalidomide) and Velcade® (bortezomib) and have demonstrated disease progression on or within 60 days of completion of the last therapy. What is the […]

  • Pomalyst®

    Class: Biological Therapy Generic Name:Pomalidomide Trade Name: Pomalyst® For which conditions is this drug approved?Pomalyst is indicated for patients with multiple myeloma who have received at least two prior therapies including Revlimid® (lenalidomide) and Velcade® (bortezomib) and have demonstrated disease progression on or within 60 days of completion of the last therapy. What is the […]

  • Kadcyla®

    Class: Biological Therapy Generic Name: ado-trastuzumab emtansine Trade Name: Kadcyla® For which conditions is this drug approved? Kadcyla is indicated as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer who previously received Herceptin® (trastuzumab) and a taxane, separately or in combination. In order to receive Kadcyla, patients should have either received […]

  • Ado-trastuzumab emtansine

    Class: Biological Therapy Generic Name: ado-trastuzumab emtansine Trade Name: Kadcyla® For which conditions is this drug approved? Kadcyla is indicated as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer who previously received Herceptin® (trastuzumab) and a taxane, separately or in combination. In order to receive Kadcyla, patients should have either received […]

  • Trametinib

    Class: Biological Therapy Generic Name:Trametinib Trade Name:MEKINIST® For which conditions is this drug approved? MEKINIST is indicated for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic melanoma with a specific type of BRAF mutation (BRAF V600E or V600K), as detected by an FDA-approved test. What is the mechanism of […]

  • MEKINIST®

    Class: Biological Therapy Generic Name:Trametinib Trade Name:MEKINIST® For which conditions is this drug approved? MEKINIST is indicated for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic melanoma with a specific type of BRAF mutation (BRAF V600E or V600K), as detected by an FDA-approved test. What is the mechanism of […]

  • TAFINLAR®

    Class: Biological Therapy Generic Name:Dabrafenib Trade Name:TAFINLAR® For which conditions is this drug approved? TAFINLAR isindicated as a single agent for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test. TAFINLAR is also indicated in combination with MEKINIST® (trametinib) […]

  • Dabrafenib

    Class: Biological Therapy Generic Name:Dabrafenib Trade Name:TAFINLAR® For which conditions is this drug approved? TAFINLAR isindicated as a single agent for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test. TAFINLAR is also indicated in combination with MEKINIST® (trametinib) […]

  • IMBRUVICA®

    Generic Name:  Ibrutinib Trade Name:  IMBRUVICA® For which conditions is this drug approved? IMBRUVICA is indicated for treatment of mantle cell lymphoma (MCL) for chronic lymphocytic leukemia (CLL), both in patients who have received at least one prior therapy;  and for Waldenström’s macroglobulinemia. What is the mechanism of action? IMBRUVICA is a tyrosine kinase inhibitor. These drugs […]

  • Ibrutinib

    Generic Name:  Ibrutinib Trade Name:  IMBRUVICA® For which conditions is this drug approved? IMBRUVICA is indicated for treatment of mantle cell lymphoma (MCL) for chronic lymphocytic leukemia (CLL), both in patients who have received at least one prior therapy; and for Waldenström’s macroglobulinemia. What is the mechanism of action? IMBRUVICA is a tyrosine kinase inhibitor. These drugs work […]

  • Sipuleucel-T

    Class: Biological Therapy Generic Name: Sipuleucel-T Trade Name: Provenge® How is this drug used? Provenge is used for the treatment of prostate cancer that has few or no symptoms, but has spread to other parts of the body and does not respond to hormone therapy (metastatic, hormone-refractory prostate cancer). What is the mechanism of action? […]

  • Tafinlar ®

    Class: Biological Therapy Generic Name: dabrafenib Trade Name: Tafinlar ® How is this drug used? Tafinlar is used for the treatment of melanoma that has metastasized or cannot surgically removed and that tests positive for a specific mutation (V600E) in the BRAF gene. What is the mechanism of action? Approximately half of all late-stage melanomas […]

  • dabrafenib

    Class: Biological Therapy Generic Name: dabrafenib Trade Name: Tafinlar ® How is this drug used? Tafinlar is used for the treatment of melanoma that has metastasized or cannot surgically removed and that tests positive for a specific mutation (V600E) in the BRAF gene. What is the mechanism of action? Approximately half of all late-stage melanomas […]

  • ruxolitinib

    Class:  Biological Therapy Generic Name:  ruxolitinib Trade Name:  Jakafi® How is this drug used? Jakafi is used to treat intermediate or high-risk myelofibrosis (a disorder of the bone marrow) and polycythemia vera with patients who have had inadequate response to or are intolerant of hydroxyurea. What is the mechanism of action? Jakafi inhibits two enzymes—JAK1 and JAK2—that […]

  • Jakafi®

    Class: Biological Therapy Generic Name:  Ruxolitinib Trade Name:  Jakafi® How is this drug used? Jakafi is used to treat intermediate or high-risk myelofibrosis (a disorder of the bone marrow) and polycythemia vera with patients who have had inadequate response to or are intolerant of hydroxyurea. What is the mechanism of action? Jakafi inhibits two enzymes—JAK1 and […]

  • bosutinib

    Class: Biological Therapy Generic Name: bosutinib Trade Name: Bosulif® How is this drug used? Bosulif is used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults with resistance or intolerance to prior therapy. What is the mechanism of action? Bosulif is a kinase inhibitor. It limits cancer growth by interfering with certain […]

  • Bosulif®

    Class: Biological Therapy Generic Name: bosutinib Trade Name: Bosulif® How is this drug used? Bosulif is used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults with resistance or intolerance to prior therapy. What is the mechanism of action? Bosulif is a kinase inhibitor. It limits cancer growth by interfering with certain […]

  • Regorafenib

    Class: Biological therapy Generic Name: Regorafenib Trade Name: Stivarga® How is this drug used? Stivarga is used to treat patients with metastatic colorectal cancer that has previously been treated with certain types of chemotherapy and other medications. What is the mechanism of action? Stivarga is a type of drug known as a multi-kinase inhibitor. It […]

  • Stivarga®

    Class: Biological therapy Generic Name: Regorafenib Trade Name: Stivarga® How is this drug used? Stivarga is used to treat patients with metastatic colorectal cancer that has previously been treated with certain types of chemotherapy and other medications. What is the mechanism of action? Stivarga is a type of drug known as a multi-kinase inhibitor. It […]

  • carfilzomib

    Class: Biological Therapy Generic Name: carfilzomib Trade Name: Kyprolis® How is this drug used? Kyprolis is used to treat multiple myeloma that is worsening and that has previously been treated with Velcade® (bortezomib) and an immunomodulatory drug such as thalidomide or lenalidomide. What is the mechanism of action? Kyprolis is a type of targeted drug known […]

  • Ziv-aflibercept

    Class: Biological therapy Generic Name: Ziv-aflibercept Trade Name: Zaltrap® How is this drug used? Zaltrap is used in combination with FOLFIRI chemotherapy for the treatment of metastatic colorectal cancer that is resistant to, or has worsened after, oxaliplatin-containing chemotherapy. What is the mechanism of action? Zaltrap is a type of drug known as an angiogenesis […]

  • Pertuzumab

    Class: Biological Therapy Generic Name: Pertuzumab Trade Name: Perjeta™ How is this drug used? Perjeta is used for the treatment of HER2-positive, metastatic breast cancer. It is given in combination with Herceptin® (trastuzumab) and Taxotere® (docetaxel), and is intended for people who have not previously been treated with chemotherapy or HER2-targeted therapy for metastatic breast […]

  • Kyprolis®

    Class: Biological Therapy Generic Name: carfilzomib Trade Name: Kyprolis® How is this drug used? Kyprolis is used to treat multiple myeloma that is worsening and that has previously been treated with Velcade® (bortezomib) and an immunomodulatory drug such as thalidomide or lenalidomide. What is the mechanism of action? Kyprolis is a type of targeted drug known […]

  • Zaltrap®

    Class: Biological therapy Generic Name: Ziv-aflibercept Trade Name: Zaltrap® How is this drug used? Zaltrap is used in combination with FOLFIRI chemotherapy for the treatment of metastatic colorectal cancer that is resistant to, or has worsened after, oxaliplatin-containing chemotherapy. What is the mechanism of action? Zaltrap is a type of drug known as an angiogenesis […]

  • Perjeta™

    Class: Biological Therapy Generic Name: Pertuzumab Trade Name: Perjeta™ How is this drug used? Perjeta is used for the treatment of HER2-positive, metastatic breast cancer. It is given in combination with Herceptin® (trastuzumab) and Taxotere® (docetaxel), and is intended for people who have not previously been treated with chemotherapy or HER2-targeted therapy for metastatic breast […]

  • Provenge®

    Class: Biological Therapy Generic Name: Sipuleucel-T Trade Name: Provenge® How is this drug used? Provenge is used for the treatment of prostate cancer that has few or no symptoms, but has spread to other parts of the body and does not respond to hormone therapy (metastatic, hormone-refractory prostate cancer). What is the mechanism of action? […]

  • Erivedge™

    Class: Biological Therapy Generic Name: vismodegib Trade Name: Erivedge™ How is this drug used? Erivedge is approved for the treatment of adults with basal cell carcinoma of the skin that has spread to other parts of the body or that has come back after surgery or cannot be treated with surgery or radiation. It is […]

  • Vemurafenib

    Class: Biological Therapy Generic Name: vemurafenib Trade Name: Zelboraf™ How is this drug used? Zelboraf is used for the treatment of melanoma that has metastasized or cannot surgically removed and that tests positive for a specific mutation (V600E) in the BRAF gene. What is the mechanism of action? Approximately half of all late-stage melanomas have […]